• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

维甲酸受体-α特异性酰胺的合成及生物活性

Synthesis and biological activity of retinoic acid receptor-alpha specific amides.

作者信息

Beard Richard L, Duong Tien T, Teng Min, Klein Elliott S, Standevan Andrew M, Chandraratna Roshantha A S

机构信息

Retinoid Research, Department of Chemistry, Allergan Inc., Irvine, CA 92623-9534, USA.

出版信息

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8. doi: 10.1016/s0960-894x(02)00647-9.

DOI:10.1016/s0960-894x(02)00647-9
PMID:12372520
Abstract

Retinoids are analogues of all-trans-retinoic acid, a powerful hormone that mediates many fundamental biological processes. Cancer and other serious hyperproliferative diseases are attractive therapeutic targets for retinoids, but the therapeutic use of retinoids is limited due to severe toxicity. We report here the design of retinoid receptor-alpha specific ligands with growth inhibitory activity in breast cancer cell lines, and which do not cause the cutaneous toxicity associated with the currently available nonselective retinoid agonists.

摘要

类视黄醇是全反式视黄酸的类似物,全反式视黄酸是一种强大的激素,介导许多基本的生物学过程。癌症和其他严重的过度增殖性疾病是类视黄醇有吸引力的治疗靶点,但由于严重的毒性,类视黄醇的治疗用途受到限制。我们在此报告了在乳腺癌细胞系中具有生长抑制活性且不会引起与目前可用的非选择性类视黄醇激动剂相关的皮肤毒性的类视黄醇受体α特异性配体的设计。

相似文献

1
Synthesis and biological activity of retinoic acid receptor-alpha specific amides.维甲酸受体-α特异性酰胺的合成及生物活性
Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8. doi: 10.1016/s0960-894x(02)00647-9.
2
Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells.维甲酸受体α的激活足以在SK-BR-3和T47D人乳腺癌细胞中充分诱导类视黄醇反应。
Cancer Res. 2000 Oct 1;60(19):5479-87.
3
Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.无论雌激素受体状态如何,维甲酸受体α的表达都与类维生素A诱导的人乳腺癌细胞生长抑制相关。
Cancer Res. 1997 Jul 1;57(13):2642-50.
4
Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids.MCF10A系列细胞系中的乳腺癌进展与视黄酸和视黄醇X受体的改变以及对视黄醇的不同反应有关。
Int J Oncol. 2004 Oct;25(4):961-71.
5
Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells.类视黄醇与视黄酸受体α的结合亲和力与类视黄醇对雌激素受体阳性MCF-7乳腺癌细胞生长抑制作用的相关性。
Cancer Res. 1995 Oct 1;55(19):4446-51.
6
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.含杂芳族羧酸取代的芪类视黄酸类似物的合成及其构效关系
J Med Chem. 1995 Jul 21;38(15):2820-9. doi: 10.1021/jm00015a004.
7
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors.杂芳维甲酸类化合物通过RAR和RXR视黄酸受体在体外和体内抑制头颈癌细胞系。
J Med Chem. 1999 Oct 21;42(21):4434-45. doi: 10.1021/jm990292i.
8
[Synthetic retinoids. Selectivity for receptors and biologic activity].
J Pharm Belg. 1994 May-Jun;49(3):221-5.
9
Receptor-selective retinoid agonists and teratogenic activity.受体选择性类视黄醇激动剂与致畸活性。
Drug Metab Rev. 1996 Feb-May;28(1-2):105-19. doi: 10.3109/03602539608993994.
10
A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions.过氧化物酶体增殖物激活受体γ的配体、视黄酸与乳腺肿瘤前病变的预防
J Natl Cancer Inst. 2000 Mar 1;92(5):418-23. doi: 10.1093/jnci/92.5.418.

引用本文的文献

1
Retinoic acid signaling and metabolism in heart failure.心力衰竭中的视黄酸信号传导与代谢
Am J Physiol Heart Circ Physiol. 2025 Apr 1;328(4):H792-H813. doi: 10.1152/ajpheart.00871.2024. Epub 2025 Feb 11.
2
Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies.基于药效团的虚拟筛选、分子对接和分子动力学模拟研究发现新型 RARα 激动剂。
PLoS One. 2023 Aug 24;18(8):e0289046. doi: 10.1371/journal.pone.0289046. eCollection 2023.
3
Prediction and Demonstration of Retinoic Acid Receptor Agonist Ch55 as an Antifibrotic Agent in the Dermis.
预测并验证维甲酸受体激动剂 Ch55 在真皮组织中的抗纤维化作用。
J Invest Dermatol. 2023 Sep;143(9):1724-1734.e15. doi: 10.1016/j.jid.2023.01.024. Epub 2023 Feb 17.
4
Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review.新型 RARα 和 RARβ 激动剂的设计:口服生物利用度药物的进展。一篇综述。
Bioorg Med Chem. 2020 Oct 15;28(20):115664. doi: 10.1016/j.bmc.2020.115664. Epub 2020 Jul 29.
5
RARG Gene Dysregulation in Acute Myeloid Leukemia.急性髓系白血病中的视黄酸受体γ基因失调
Front Mol Biosci. 2019 Oct 24;6:114. doi: 10.3389/fmolb.2019.00114. eCollection 2019.
6
Discovery of retinoic acid receptor agonists as proliferators of cardiac progenitor cells through a phenotypic screening approach.通过表型筛选方法发现维甲酸受体激动剂作为心脏祖细胞的增殖剂。
Stem Cells Transl Med. 2020 Jan;9(1):47-60. doi: 10.1002/sctm.19-0069. Epub 2019 Sep 11.
7
Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.生成功能正常的中性粒细胞以减少癌症化疗中的感染和感染相关死亡率的策略。
Pharmacol Ther. 2019 Dec;204:107403. doi: 10.1016/j.pharmthera.2019.107403. Epub 2019 Aug 27.
8
The Pleiotropic Role of Retinoic Acid/Retinoic Acid Receptors Signaling: From Vitamin A Metabolism to Gene Rearrangements in Acute Promyelocytic Leukemia.维 A 酸/维 A 酸受体信号的多效性作用:从维生素 A 代谢到急性早幼粒细胞白血病中的基因重排。
Int J Mol Sci. 2019 Jun 14;20(12):2921. doi: 10.3390/ijms20122921.
9
Potential role for all- retinoic acid in nonpromyelocytic acute myeloid leukemia.全反式维甲酸在非早幼粒细胞性急性髓细胞白血病中的潜在作用。
Int J Hematol Oncol. 2016 Dec;5(4):133-142. doi: 10.2217/ijh-2016-0015. Epub 2017 Mar 14.
10
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.设计并合成一种高效、高选择性、可口服、类视黄醇 X 受体 α 激动剂。
Bioorg Med Chem. 2018 Feb 15;26(4):798-814. doi: 10.1016/j.bmc.2017.12.015. Epub 2017 Dec 9.